home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.15 +1.38 (+2.57%)

Official Closing Price Updated: 4:15 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

34 35 Next >

Why Editas Medicine Stock Is Soaring Today ↗

September 29, 2023

Investors are cheering a big analyst upgrade for the gene-editing stock.

Via The Motley Fool

If I Could Only Buy 3 Stocks in 2023, I'd Pick These ↗

September 29, 2023

These stocks have what it takes to grow in leaps and bounds.

Via The Motley Fool

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment ↗

September 28, 2023

The FDA is within three months of making a decision on the first-ever CRISPR-based drug.

Via Investor's Business Daily

2 Bargain Growth Stocks to Buy Hand Over Fist ↗

September 28, 2023

Both stocks have declined in recent times.

Via The Motley Fool

Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher ↗

September 27, 2023

These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher.

Via InvestorPlace

From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects ↗

September 27, 2023

Are you looking to invest in undervalued stocks? Here are sever undervalued stocks with sparkling prospects.

Via InvestorPlace

2 No-Brainer Biotech Stocks to Buy Right Now ↗

September 12, 2023

You can get in early on these potential winners.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗

September 27, 2023

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

2 Cathie Wood Stocks to Buy Hand Over Fist Right Now ↗

September 24, 2023

These two high-tech stocks could dramatically outperform the broader market in the years ahead.

Via The Motley Fool

$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years ↗

September 21, 2023

I favor holding onto these players for the long term to truly benefit from their earnings potential.

Via The Motley Fool

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio ↗

September 20, 2023

These two biotechs have a lot in common, but one is much better capitalized.

Via The Motley Fool

Flee to Healthcare Stocks if Recession Rears its Head?

September 20, 2023

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

Via MarketBeat

Topics Economy

Where Will CRISPR Therapeutics Be in 5 Years? ↗

September 19, 2023

The company hasn't performed well in the past five years, but things could change.

Via The Motley Fool

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know ↗

September 19, 2023

Good medicines aren't always good business.

Via The Motley Fool

2 Top Trends to Invest $500 In Right Now ↗

September 18, 2023

Early investors in these trends may reap the rewards over time.

Via The Motley Fool

Looking for Growth? These Companies' Revenue May Skyrocket ↗

September 17, 2023

Catalysts on the horizon could drive gains in these top stocks.

Via The Motley Fool

If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today ↗

September 16, 2023

The returns are impressive, but will they continue to be so?

Via The Motley Fool

Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics ↗

September 15, 2023

They're both liable to grow by a lot, but one of them is a safer bet in the near term.

Via The Motley Fool

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

3 Top Healthcare Stocks Defying the Bear Market ↗

September 15, 2023

Revenue at all three companies improved last quarter, and their share prices have followed suit.

Via The Motley Fool

Better Bull Market Buy: CRISPR vs. Medtronic Stock ↗

September 14, 2023

Investors may look for growth stocks ahead of the next bull market.

Via The Motley Fool

3 Biotech Blockbusters to Turn $5,000 Into $50,000 ↗

September 12, 2023

These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time.

Via InvestorPlace

More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics ↗

September 12, 2023

These companies are innovators, something that can prove highly lucrative.

Via The Motley Fool

CRSP Stock Alert: What to Know as CRISPR Therapeutics Co-Founder Steps Down ↗

September 07, 2023

With CRISPR Therapeutics announcing the departure of its co-founder, investors are also walking for the exits on CRSP stock.

Via InvestorPlace

2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street ↗

September 06, 2023

Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months.

Via The Motley Fool

With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock? ↗

September 05, 2023

Big news could come in December and in March.

Via The Motley Fool

The 3 Best Biotech Stocks to Buy Now: September 2023 ↗

September 04, 2023

With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.

Via InvestorPlace

2 Spectacular Growth Stocks You Can Buy in September With No Hesitation ↗

September 03, 2023

There's no need for any anxiety with investing in these great stocks.

Via The Motley Fool

3 Beaten-Down Biotech Stocks Bound for a Bounce Back ↗

September 02, 2023

Biotech stocks are still below their post-pandemic peaks. But these beaten-down biotech stocks could lead the sector to new highs.

Via InvestorPlace

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com